Live Breaking News & Updates on Cyclo Therapeutics Inc
Stay updated with breaking news from Cyclo therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Founders Fund VI Management LLC purchased a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics comprises […] ....
Founders Fund V Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics accounts for 80.8% of Founders Fund V Management […] ....
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright assumed coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a research report sent to investors on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q1 2024 earnings at ($0.20) EPS, Q2 2024 […] ....